DOPA Decarboxylase Modulates Tau Toxicity

Biological Psychiatry

Volumn 83, Issue 5, 2018, Pages 438-446

  Kow, Rebecca L ^a,b   Sikkema, Carl ^a,b   Wheeler, Jeanna M ^a   Wilkinson, Charles W ^a,b   Kraemer, Brian C ^a,b,c  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Aromatic amino acid decarboxylase; DOPA decarboxylase; Dopamine; Neurodegeneration; Serotonin; Tau

Indexed keywords

5 HYDROXYTRYPTOPHAN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; DOPAMINE 2 RECEPTOR; LEVODOPA; SEROTONIN; TAU PROTEIN; CAENORHABDITIS ELEGANS PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DOPAMINE METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TAUOPATHY; TRANSGENE; YOUNG ADULT; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; GENETICS; METABOLISM; PHYSIOLOGY; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BEHAVIOR, ANIMAL; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; DISEASE MODELS, ANIMAL; DOPA DECARBOXYLASE; DOPAMINE; SEROTONIN; TAU PROTEINS; TAUOPATHIES;

EID: 85025446487     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2017.06.007     Document Type: Article

References (36)

1. Wang, Y., Mandelkow, E., Tau in physiology and pathology. Nat Neurosci 17 (2016), 5–21.
2. Khanna, M.R., Kovalevich, J., Lee, V.M., Trojanowski, J.Q., Brunden, K.R., Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimers Dement 12 (2016), 1051–1065.
3. McCormick, A.V., Wheeler, J.M., Guthrie, C.R., Liachko, N.F., Kraemer, B.C., Dopamine D2 Receptor antagonism suppresses tau aggregation and neurotoxicity. Biol Psychiatry 73 (2013), 464–471.
4. Kraemer, B.C., Zhang, B., Leverenz, J.B., Thomas, J.H., Trojanowski, J.Q., Schellenberg, G.D., Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A 100 (2003), 9980–9985.
5. Chiba, S., Takada, E., Tadokoro, M., Taniguchi, T., Kadoyama, K., Takenokuchi, M., et al. Loss of dopaminoreceptive neuron causes L-dopa resistant parkinsonism in tauopathy. Neurobiol Aging 33 (2012), 2491–2505.
6. Wu, T.H., Lu, Y.N., Chuang, C.L., Wu, C.L., Chiang, A.S., Krantz, D.E., et al. Loss of vesicular dopamine release precedes tauopathy in degenerative dopaminergic neurons in a Drosophila model expressing human tau. Acta Neuropathol 125 (2013), 711–725.
7. Lebel, M., Patenaude, C., Allyson, J., Massicotte, G., Cyr, M., Dopamine D1 receptor activation induces tau phosphorylation via cdk5 and GSK3 signaling pathways. Neuropharmacology 57 (2009), 392–402.
8. Koppel, J., Jimenez, H., Adrien, L., Greenwald, B.S., Marambaud, P., Cinamon, E., et al. Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease. Alzheimers Dement Transl Res Clin Interv 2 (2016), 121–130.
9. Tyler, M.W., Zaldivar-Diez, J., Haggarty, S.J., Classics in chemical neuroscience: Haloperidol. ACS Chem Neurosci 8 (2017), 444–453.
10. Brenner, S., The genetics of Caenorhabditis elegans. Genetics 77 (1974), 71–94.
11. Liachko, N.F., Guthrie, C.R., Kramer, B.C., Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci 30 (2010), 16208–16219.
12. Beaulieu, J.M., Espinoza, S., Gainetdinov, R.R., Dopamine receptors – IUPHAR review 13. Br J Pharmacol 172 (2015), 1–23.
13. Hare, E.E., Loer, C.M., Function and evolution of the serotonin-synthetic bas-1 gene and other aromatic amino acid decarboxylase genes in Caenorhabditis. BMC Evol Biol, 4, 2004, 24.
14. Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E., Mandelkow, E.M., Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38 (1999), 3548–3558.
15. Acker, C.M., Forest, S.K., Zinkowski, R., Davies, P., d'Abramo, C., Sensitive quantitative assays for tau and phosphor-tau in transgenic mouse models. Neurobiol Aging 34 (2013), 338–350.
16. Yu, Y., Run, X., Liang, Z., Li, Y., Liu, F., Liu, Y., et al. Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J Neurochem 108 (2009), 1480–1494.
17. Eastman, C., Horvitz, H.R., Jin, Y., Coordinated transcriptional regulation of the unc-25 glutamic acid decarboxylase and the unc-47 GABA vesicular transporter by the Caenorhabditis elegans UNC-30 homeodomain protein. J Neurosci 19 (1999), 6224–6234.
18. Yin, J.A., Liu, X.J., Yuan, J., Jiang, J., Cai, S.Q., Longevity manipulations differentially affect serotonin/dopamine level and behavioral deterioration in aging Caenorhabditis elegans. J Neurosci 34 (2014), 3947–3958.
19. Sawin, E.R., Ranganathan, R., Horvitz, H.R., C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron 26 (2000), 619–631.
20. Sze, J.W., Victor, M., Loer, C., Shi, Y., Ruvkun, G., Food and metabolic signalling defects in a Caenorhabditis elegans serotonin-synthesis mutant. Nature 403 (2000), 560–564.
21. Sulston, J., Dew, M., Brenner, S., Dopaminergic neurons in the nematode Caenorhabditis elegans. J Comp Neurol 163 (1975), 215–226.
22. Loer, C.M., Kenyon, C.J., Serotonin-deficient mutants and male mating behavior in the nematode Caenorhabditis elegans. J Neurosci 13 (1993), 5407–5417.
23. Loer, C.M., Calvo, A.C., Watschinger, K., Werner-Felmayer, G., O'Rourke, D., Stroud, D., et al. Cuticle integrity and biogenic amine synthesis in Caenorhabditis elegans require the cofactor tetrahydrobiopterin (BH4). Genetics 200 (2015), 237–253.
24. Reese, L.C., Taglialatela, G., A role for calcineurin in Alzheimer's disease. Curr Neuropharmacol 9 (2011), 685–692.
25. Sengupta, A., Grundke-Iqbal, I., Iqbal, K., Regulation of phosphorylation of tau by protein kinases in rat brain. Neurochem Res 31 (2006), 1473–1480.
26. De Deurwaerdère, P., Di Giovanni, G., Millan, M.J., Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry. Prog Neurobiol 151 (2017), 57–100.
27. Larghi, E.L., Amongero, M., Bracca, A.B.J., Kaufman, T.S., The intermolecular Pictet-Spengler condensation with chiral carbonyl derivatives in the stereoselective syntheses of optically-active isoquinoline and indole alkaloids. ARKIVOC 12 (2005), 98–153.
28. Bertoldi, M., Mammalian dopa decarboxylase: Structure, catalytic activity and inhibition. Arch Biochem Biophys 546 (2014), 1–7.
29. Lebel, M., Chagniel, L., Bureau, G., Cyr, M., Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis 38 (2010), 59–67.
30. Xie, C.L., Wang, W.W., Zhang, S.F., Yuan, M.L., Che, J.Y., Gan, J., et al. Levodopa/bensarazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats. Sci Rep, 4, 2014, 7506.
31. Bottiglieri, T., Arning, E., Wasek, B., Nunbhakdi-Craig, V., Sontag, J.M., Sontag, E., Acute administration of L-Dopa induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain. J Neurosci 32 (2012), 9173–9181.
32. Salvatore, M.F., Calipari, E.S., Jones, S.R., Regulation of tyrosine hydroxylase expression and phosphorylation in dopamine transporter-deficient mice. ACS Chem Neurosci 7 (2016), 941–951.
33. Lee, N.C., Shieh, Y.D., Chien, Y.H., Tzen, K.Y., Yu, I.S., Chen, P.W., et al. Regulation of the dopaminergic system in a murine model of aromatic l-amino acid decarboxylase deficiency. Neurobiol Dis 52 (2013), 177–190.
34. Zhang, F., Bhattacharya, A., Nelson, J.C., Abe, N., Gordon, P., Lloret-Fernandez, C., et al. The LIM and POU homeobox genes ttx-3 and unc-86 act as terminal selectors in distinct cholinergic and serotonergic neuron types. Development 141 (2014), 422–435.
35. Hadjiconstatinou, M., Neff, N.H., Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson's disease. CNS Neurosci Ther 14 (2008), 340–351.
36. Schuske, K., Beg, A.A., Jorgensen, E.M., The GABA nervous system in C. elegans. Trends Neurosci 27 (2004), 407–414.